1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Safety, tolerability, and pK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): phase II shelter study

      Clin Otolaryngol

      Read this article at

      ScienceOpen
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Comments

          Comment on this article